Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Enterprise Value (2022 - 2026)

Centessa Pharmaceuticals has reported Enterprise Value over the past 5 years, most recently at -$294.6 million for Q4 2025.

  • Quarterly Enterprise Value rose 38.91% to -$294.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$294.6 million through Dec 2025, up 38.91% year-over-year, with the annual reading at -$294.6 million for FY2025, 38.91% up from the prior year.
  • Enterprise Value was -$294.6 million for Q4 2025 at Centessa Pharmaceuticals, down from -$246.2 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$230.2 million in Q1 2024 and troughed at -$595.1 million in Q4 2021.
  • The 5-year median for Enterprise Value is -$303.6 million (2023), against an average of -$367.7 million.
  • Year-over-year, Enterprise Value tumbled 87.95% in 2024 and then surged 52.51% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$595.1 million in 2021, then surged by 33.85% to -$393.6 million in 2022, then surged by 34.83% to -$256.5 million in 2023, then tumbled by 87.95% to -$482.2 million in 2024, then soared by 38.91% to -$294.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Enterprise Value are -$294.6 million (Q4 2025), -$246.2 million (Q3 2025), and -$250.7 million (Q2 2025).